People

The People — Convatec Group plc

Governance grade: B+. Clean institutional float, capable freshly-appointed CEO/CFO, and an experienced independent board — but skin-in-the-game is thin (CEO at 161% of the 500% target), the 2025 Remuneration Policy carried only 67% support, and the prior chair's £80,000 FCA fine for unlawful disclosure of inside information sits in the institution's recent memory.

The People Running This Company

The whole executive bench turned over in three months of 2025. CEO Karim Bitar — architect of the 2019–2025 turnaround — went on medical leave in August and died 26 October. The board promoted from inside: CFO Jonny Mason became interim CEO, then permanent CEO on 6 November. Group Financial Controller Fiona Ryder stepped up to interim CFO, then permanent CFO on the same day. There was no external search in the public record — a continuity bet that succession actually worked because Mason had four years inside.

The bench beneath Mason is heavily ex-pharma/medtech: Bruno Pinheiro (Ostomy) is a Bristol-Myers Squibb–Convatec lifer pre-2008 spin-out; Tanja Dormels (Advanced Wound Care, promoted Oct 2025) is ex-Sandoz/Novartis; Anne Belcher (Emerging Markets) brings 30 years of GSK; David Shepherd (Chief Commercial) brings 26 years of Johnson & Johnson; Divakar Ramakrishnan (CTO/R&D) ran Eli Lilly's drug-delivery & digital health. The CELT looks built for a chronic-care MedTech, not improvised. Walter Morse is "interim" Chief Quality & Operations — the one open seat.

What They Get Paid

Convatec discloses pay in pounds. FY2025 single-figure totals reflect a scrambled year: Bitar's £7.65m includes early-vest of 2023, 2024 and 2025 LTI awards triggered by death-in-service (£5.01m of LTI alone, computed at a £2.49 share price). Mason's £3.58m blends part-year CFO, interim CEO and permanent CEO time. Ryder's £0.75m is partial-year board service.

The 2025 annual bonus paid out at 81.6% of maximum for all three executives, driven by adjusted operating profit hitting $551m vs $550m max (100% of element), organic revenue growth of 6.2% (74% of element) and a soft FCF-to-equity outcome of $241m vs $258m target (only 32% of element). The 2023–25 LTIP vested at 85.1% of max: adjusted PBT growth and organic revenue growth both maxed; relative TSR vs FTSE 50–150 paid 0% but TSR vs the S&P Global Healthcare Equipment Index paid 80.4%.

The CEO pay ratio swelled to 233:1 (median) in 2025 from 87:1 in 2024 because Bitar's death-in-service triggered early LTI vest. The underlying ratio for Mason as the going-forward CEO will normalise lower. Pay quantum is in line with FTSE 100 / global MedTech peers; structure (200% bonus max, 525% LTI max, 5% ESG underpin, 2-year post-vest holding, malus + clawback) is conventional and well-disclosed.

Are They Aligned?

This is where governance gets uncomfortable. Convatec has no founder, no promoter, no controlling shareholder. The free float is wholly institutional, with Black Creek (5.15%), Fidelity (5.12%), BlackRock (5.0%), MFS (4.98%), Artisan (4.98%) and FMR (4.93%) all clustered just above DTR 5 disclosure. Top 20 holders own 51%; insiders together own under 1%. Discipline therefore depends on external investors, not internal economic stake.

The biggest ownership story of FY2025 was the exit of Novo Holdings (the Novo Nordisk parent), which placed its remaining 7.8% stake at 227p — a 5.1% discount to spot — on 17 November 2025, raising £351m. Novo had been on the register since the 2017 PE exit and held a board seat until 2023. Its rationale: "transformation now complete." Read it as a vote of confidence in execution but a removal of any anchor shareholder. Stock fell 4.3% on the day.

Mason buying 100,000 shares while interim CEO is the strongest single alignment signal in the file. Sharon O'Keefe selling her token 3,200-share holding in full is mildly negative — small size, large signal — though her position pre-existing was already non-meaningful.

Mason holds 50,000 outright + 1.53m vested but unexercised = ~£3.7m at 210p, equal to 161% of his £1.04m new CEO salary. Required: 500%. He has five years to build it. Ryder is at 91% versus a 300% target. Both are recently-appointed Executive Directors so the gap is structurally explicable, not necessarily a red flag — but until they are at-target, the alignment story is potential, not actual.

Capital allocation behaviour is shareholder-friendly. A non-discretionary $300m share buyback ran in 2025 to return surplus capital. Dividends grew (cash to shareholders +7.7% YoY); employee pay grew 6.6% — roughly aligned. No related-party transactions of any size are disclosed in the FY2025 governance section, and no dividend waivers exist (per UKLR 6.6.1 cross-reference). InnovaMatrix took a $72m impairment to a $40m carrying value — disclosed as adjusting and audit-committee challenged. The Audit Committee approved removing InnovaMatrix from the 2026 organic revenue bonus base and target — defensible given CMS rate cuts, but it does soften the bonus hurdle.

Score: 6/10. Pulled up by Mason's open-market buy, large buyback, no related-party dealings, and clean institutional float. Pulled down by sub-target executive ownership, no founder/promoter anchor, and the largest historical insider (Novo) just exited.

Board Quality

Of nine directors, six are formally and substantively independent (May, Coussios, H. Mason, Lody, O'Keefe, Ewing). McAdam was independent on appointment in 2019 — he is now in year seven, with the UK Code's nine-year independence ceiling visible. Margaret Ewing has eight years on the board; she is approaching the same threshold and the company's Annual Report flags she is "continuing on the Board in 2026" specifically to bridge the CEO/CFO transition. Both should be on a watch-list for refreshment.

Strengths: deep finance bench (Ewing — Deloitte/BAA/Standard Chartered; May — Bunzl 13 yrs CFO; Mason — five PLC CFO roles), and deep MedTech operating bench (H. Mason — Abbott; Lody — Coloplast; O'Keefe — UChicago Medicine; Pinheiro/Belcher/Shepherd in CELT).

Gaps: with Coussios stepping down 13-Apr-2026, the board loses its only resident scientific/R&D NED. Cyber, AI, ERP-transformation oversight is delegated to Audit & Risk and managed via external consultants — competent but not expert on-board. There is no software/digital-product NED.

External performance evaluation is conducted by Lintstock (independent). Audit firm is rotating from Deloitte to EY effective FY2026 (competitive tender) — best-practice cadence. Remuneration adviser is Willis Towers Watson (£100k fee). The Audit & Risk Committee is genuinely robust: it actively challenged the InnovaMatrix impairment, pushed back on revenue-recognition judgements, and required the ERP transformation programme to be staffed with external rigour.

The Verdict

Grade: B+.

What works:

• Independent board with credible MedTech and finance expertise.
• Internal succession was tested by the worst possible scenario (CEO death) and executed cleanly within 3.5 months.
• $300m buyback, growing dividend, no related-party transactions, no controlling shareholder.
• Mason bought 100k shares with his own money during the interim period — the cleanest possible alignment signal.
• Audit Committee genuinely challenges management; auditor rotation Deloitte → EY is well-managed.

What concerns:

• 33% voted against the new pay policy in May 2025 and the company's "engagement" was minimal — that vote will be re-litigated.
• Executive ownership is far below guideline (CEO 161% / target 500%; CFO 91% / 300%); skin-in-the-game is aspirational, not present.
• Chair (6 yrs) and SID/Audit Chair (8 yrs) approaching the UK Code's 9-year independence ceiling concurrently.
• Coussios departure removes the only deep R&D voice from the board.
• Novo Holdings' full exit removes the only large anchor shareholder.

Single biggest swing factor for re-grade:

• Upgrade to A- if Mason builds toward the 500% guideline within two years AND the 2026 AGM pay vote rebuilds to >85% support.
• Downgrade to B- if a successor R&D NED is not named promptly, OR if management uses the InnovaMatrix carve-out to engineer bonus outcomes that look detached from headline reported revenue.

Convatec is not a governance star, but it is also not a problem case. It is a competently-run, independent-board FTSE 100 medtech where the alignment economics still need to be earned by the new CEO.